TY - JOUR
T1 - Congenital cytomegalovirus in Japan
T2 - More than 2 year follow up of infected newborns
AU - the Japanese Congenital Cytomegalovirus Study Group
AU - Koyano, Shin
AU - Morioka, Ichiro
AU - Oka, Akira
AU - Moriuchi, Hiroyuki
AU - Asano, Kimisato
AU - Ito, Yushi
AU - Yoshikawa, Tetsushi
AU - Yamada, Hideto
AU - Suzutani, Tatsuo
AU - Inoue, Naoki
N1 - Publisher Copyright:
© 2017 Japan Pediatric Society
PY - 2018/1
Y1 - 2018/1
N2 - Background: The aim of this study was to evaluate the outcome of congenital cytomegalovirus (CMV) infection identified on urine-filter screening assay at >2 years’ follow up, and to observe the clinical outcomes after anti-CMV treatment. Methods: Sixty of 72 congenital CMV patients were enrolled and clinically observed for >2 years. Forty-three were asymptomatic at birth; seven were symptomatic at birth but untreated with anti-CMV drugs; and 10 were symptomatic and treated with anti-CMV drugs. Results: Of the 43 asymptomatic patients, three developed hearing loss or language disability for which association with congenital CMV has been repeatedly reported, and two had neurological sequelae of which the etiology was unclear, indicating that the rate of CMV-associated late-onset sequelae was 7–12%. All seven symptomatic infants without treatment developed sequelae, while three of the 10 treated patients were free from any sequelae. Conclusions: The rate of late-onset sequelae observed in Japan is similar to that reported in the USA and Europe. The treatment of symptomatic patients with antiviral agents results in favorable clinical outcomes. Thus, newborn urine–filter paper screening of congenital CMV infection is warranted.
AB - Background: The aim of this study was to evaluate the outcome of congenital cytomegalovirus (CMV) infection identified on urine-filter screening assay at >2 years’ follow up, and to observe the clinical outcomes after anti-CMV treatment. Methods: Sixty of 72 congenital CMV patients were enrolled and clinically observed for >2 years. Forty-three were asymptomatic at birth; seven were symptomatic at birth but untreated with anti-CMV drugs; and 10 were symptomatic and treated with anti-CMV drugs. Results: Of the 43 asymptomatic patients, three developed hearing loss or language disability for which association with congenital CMV has been repeatedly reported, and two had neurological sequelae of which the etiology was unclear, indicating that the rate of CMV-associated late-onset sequelae was 7–12%. All seven symptomatic infants without treatment developed sequelae, while three of the 10 treated patients were free from any sequelae. Conclusions: The rate of late-onset sequelae observed in Japan is similar to that reported in the USA and Europe. The treatment of symptomatic patients with antiviral agents results in favorable clinical outcomes. Thus, newborn urine–filter paper screening of congenital CMV infection is warranted.
KW - anti-cytomegalovirus drug treatment
KW - congenital cytomegalovirus infection
KW - follow up
KW - late-onset sequelae
KW - newborn screening
UR - http://www.scopus.com/inward/record.url?scp=85040810441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040810441&partnerID=8YFLogxK
U2 - 10.1111/ped.13433
DO - 10.1111/ped.13433
M3 - Article
C2 - 29032597
AN - SCOPUS:85040810441
SN - 1328-8067
VL - 60
SP - 57
EP - 62
JO - Pediatrics International
JF - Pediatrics International
IS - 1
ER -